Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.31 |
| ▸ | FLI1 | Q01543 | 1/20 | 0.30 |
| ▸ | EWSR1 | Q01844 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11974149 | 0.89 | FOLH1 (0.34) | TDP1FOLH1F2PRSS1PRSS2 | |
| SCHEMBL11983829 | 0.87 | TDP1 (0.42) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL11974139 | 0.86 | TDP1 (0.36) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL21361160 | 0.86 | TDP1 (0.53) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL21361152 | 0.76 | TDP1 (0.42) | TDP1FOLH1CNR1PRSS1PRSS2 | |
| SCHEMBL21361151 | 0.76 | TDP1 (0.63) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL21361155 | 0.75 | TDP1 (0.49) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL21361157 | 0.72 | TDP1 (0.61) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL21361159 | 0.72 | TDP1 (0.55) | TDP1FOLH1CNR1F2PRSS1 | |
| SCHEMBL11974147 | 0.72 | TDP1 (0.33) | TDP1FOLH1F2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120207684-A1 | COMPOSITION AND METHODS FOR IMAGING CELLS | CASE WESTERN RESERVE UNIVERSITY | 2012-08-16 | — | — | US | disclosed |
| US-20120207684-A1 | COMPOSITION AND METHODS FOR IMAGING CELLS | CASE WESTERN RESERVE UNIVERSITY | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207684-A1 | COMPOSITION AND METHODS FOR IMAGING CELLS | MCL1, TP53, HNRNPAB | TDP1 3017/4885FOLH1 262/4885CNR1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.